Literature DB >> 18635526

Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure.

Quanri Jin1, David G Menter, Li Mao, Waun Ki Hong, Ho-Young Lee.   

Abstract

The inhibitor of apoptosis protein survivin is selectively expressed in tumor cells. The tobacco component nicotine increases the transcription of the survivin gene in non-small cell lung cancer cells. However, the role of survivin expression induced by tobacco component is not clear during lung carcinogenesis. We investigated the effects of the tobacco components nicotine and its related carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) on survivin expression in normal human bronchial epithelial (NHBE) cells and examined the role of survivin in the malignant transformation of normal human bronchial epithelial (HBE) cells induced by these components. We found that survivin messenger RNA (mRNA) expression was detected in 41% (7 of 17) of bronchial brush specimens from heavy smokers. Nicotine and NNK increased survivin mRNA and protein expression levels in primary cultured NHBE cells and immortalized HBE cells. Bronchial epithelium in mice administered NNK also showed increased staining for survivin. Nicotine and NNK stimulated the Akt-mammalian target of rapamycin (mTOR) pathway in NHBE cells, leading to increased de novo synthesis of survivin protein. Induced survivin expression increased the survival potential of the cells, which was blocked by transfection with survivin-specific small interfering RNA (siRNA). siRNA-induced down-regulation of survivin expression also suppressed the tumorigenic potential of premalignant and malignant HBE cells exposed to the tobacco components. These findings suggest that NNK and nicotine induce survivin protein synthesis in NHBE cells by activating the Akt-mTOR pathway and thus blockade of the pathway effectively inhibits the tobacco-induced malignant transformation of HBE cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635526      PMCID: PMC2516487          DOI: 10.1093/carcin/bgm234

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  48 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Nuclear export is essential for the tumor-promoting activity of survivin.

Authors:  Shirley K Knauer; Oliver H Krämer; Thomas Knösel; Knut Engels; Franz Rödel; Adorján F Kovács; Wolfgang Dietmaier; Ludger Klein-Hitpass; Negusse Habtemichael; Andrea Schweitzer; Jürgen Brieger; Claus Rödel; Wolf Mann; Iver Petersen; Thorsten Heinzel; Roland H Stauber
Journal:  FASEB J       Date:  2006-11-10       Impact factor: 5.191

3.  Effects of human papillomavirus type 16 oncoproteins on survivin gene expression.

Authors:  Agnes A Borbély; Melinda Murvai; József Kónya; Zoltán Beck; Lajos Gergely; Fengzhi Li; György Veress
Journal:  J Gen Virol       Date:  2006-02       Impact factor: 3.891

4.  Expression of survivin and Bcl-2 in the normal human endometrium.

Authors:  R Konno; H Yamakawa; H Utsunomiya; K Ito; S Sato; A Yajima
Journal:  Mol Hum Reprod       Date:  2000-06       Impact factor: 4.025

Review 5.  Apoptosis in cancer.

Authors:  S W Lowe; A W Lin
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

6.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers.

Authors:  M Monzó; R Rosell; E Felip; J Astudillo; J J Sánchez; J Maestre; C Martín; A Font; A Barnadas; A Abad
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

7.  Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.

Authors:  C Du; M Fang; Y Li; L Li; X Wang
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

8.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin.

Authors:  D S O'Connor; D Grossman; J Plescia; F Li; H Zhang; A Villa; S Tognin; P C Marchisio; D C Altieri
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

9.  PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Authors:  Hongbing Zhang; Natalia Bajraszewski; Erxi Wu; Hongwei Wang; Annie P Moseman; Sandra L Dabora; James D Griffin; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

10.  Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin.

Authors:  Quanri Jin; Lei Feng; Carmen Behrens; B Nebiyou Bekele; Ignacio I Wistuba; Waun-Ki Hong; Ho-Young Lee
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

View more
  16 in total

1.  The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis.

Authors:  Regan M Memmott; Phillip A Dennis
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

2.  Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma.

Authors:  Mariana Brait; Enrico Munari; Cynthia LeBron; Maartje G Noordhuis; Shahnaz Begum; Christina Michailidi; Nilda Gonzalez-Roibon; Leonel Maldonado; Tanusree Sen; Rafael Guerrero-Preston; Leslie Cope; Paola Parrella; Vito Michele Fazio; Patrick K Ha; George J Netto; David Sidransky; Mohammad O Hoque
Journal:  Cell Cycle       Date:  2013-02-22       Impact factor: 4.534

3.  Differentially localized survivin and STAT3 as markers of gastric cancer progression: Association with Helicobacter pylori.

Authors:  Arvind Pandey; Satyendra Chandra Tripathi; Shirish Shukla; Sutapa Mahata; Kanchan Vishnoi; Sri Prakash Misra; Vatsala Misra; Sankar Mitra; Manisha Dwivedi; Alok C Bharti
Journal:  Cancer Rep (Hoboken)       Date:  2018-06-01

4.  Depletion of K-Ras promotes proteasome degradation of survivin.

Authors:  Awet Tecleab; Saïd M Sebti
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

5.  Association of cigarette smoking with the expression of nuclear survivin in pathological Stage IA lung adenocarcinomas.

Authors:  Hiroshi Hirano; Hajime Maeda; Yukiyasu Takeuchi; Yoshiyuki Susaki; Ryoji Kobayashi; Akio Hayashi; Naoko Ose; Yukie Nakazawa; Toshihiko Yamaguchi; Soichiro Yokota; Masahide Mori
Journal:  Med Mol Morphol       Date:  2013-11-09       Impact factor: 2.309

6.  A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.

Authors:  Young-Ah Suh; Jai-Hyun Kim; Myung A Sung; Hye-Jin Boo; Hye Jeong Yun; Sun-Hye Lee; Hyo-Jong Lee; Hye-Young Min; Young-Ger Suh; Kyu-Won Kim; Ho-Young Lee
Journal:  Cancer Lett       Date:  2013-01-21       Impact factor: 8.679

7.  Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.

Authors:  Quanri Jin; Linda X Yuan; Delphine Boulbes; Jong Min Baek; Ying Nai Wang; Daniel Gomez-Cabello; David H Hawke; Sai Ching Yeung; Mong Hong Lee; Gabriel N Hortobagyi; Mien Chie Hung; Francisco J Esteva
Journal:  Breast Cancer Res       Date:  2010-11-16       Impact factor: 6.466

8.  Epigenetic effects and molecular mechanisms of tumorigenesis induced by cigarette smoke: an overview.

Authors:  Rong-Jane Chen; Louis W Chang; Pinpin Lin; Ying-Jan Wang
Journal:  J Oncol       Date:  2011-03-22       Impact factor: 4.375

9.  Nicotine Inhibits Cisplatin-Induced Apoptosis via Regulating α5-nAChR/AKT Signaling in Human Gastric Cancer Cells.

Authors:  Yanfei Jia; Haiji Sun; Hongqiao Wu; Huilin Zhang; Xiuping Zhang; Dongjie Xiao; Xiaoli Ma; Yunshan Wang
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

10.  Curcumin and vitamin E protect against adverse effects of benzo[a]pyrene in lung epithelial cells.

Authors:  Wenbin Zhu; Meghan M Cromie; Qingsong Cai; Tangfeng Lv; Kamaleshwar Singh; Weimin Gao
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.